Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924
This study is recruiting at 18 US sites in 14 states, according to its ClinicalTrials.gov record last updated .
Summary
BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non-small Cell Lung Cancer
- Histiocytic Neoplasm
- Histiocytosis
- BRAF Gene Mutation
- BRAF V600E
- BRAF V600 Mutation
- BRAF Mutation-Related Tumors
- BRAF
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Cancer
- Recurrent Lung Cancer
- Recurrent Lung Non-Small Cell Carcinoma
- NSCLC
- Solid Tumor
- Solid Carcinoma
- KRAS G12D
- KRAS G12V
- KRAS Mutation-Related Tumors
- NRAS Gene Mutation
- Thyroid Cancer
- Thyroid Carcinoma
- Colorectal Cancer
- Colorectal Carcinoma
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- Brain Metastases
- Recurrent NSCLC
- KRAS G13C
- Acquired Resistance to KRAS G12C Inhibitor
- KRAS G12A
- KRAS G12F
- KRAS G12R
- KRAS G13D
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Institut de Recherches Internationales Servier
- Last updated on ClinicalTrials.gov
- October 13, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Banner Health- MD Anderson Cancer Center · Gilbert, AZ
California · 3
- The Angeles clinic - A cedars SINAI AFFILIATE · Los Angeles, CA
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
- University of California, San Francisco (UCSF) · San Francisco, CA
Connecticut · 1
- Yale University School of Medicine - Yale Cancer Center · New Haven, CT
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Michigan · 1
- South Texas Accelerated Research Therapeutics (START) Midwest · Grand Rapids, MI
Minnesota · 1
- Masonic Cancer Center University of Minnesota · Minneapolis, MN
Missouri · 1
- Washington University · St Louis, MO
New York · 2
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) · New York, NY
North Carolina · 1
- Duke University School of Medicine · Durham, NC
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Tennessee · 1
- Sarah Canon Research Institute (SCRI) Oncology Partners · Nashville, TN
Texas · 2
- MD Anderson Cancer Center · Houston, TX
- START San Antonio · San Antonio, TX
Virginia · 1
- NEXT Virginia · Fairfax, VA
Washington · 1
- Fred Hutchinson Cancer Research Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.